Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06962865 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 16, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 15, 2025 to Jun 30, 2025 · Site details revised at 34 of 34 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Jun 15, 2025 to Jun 30, 2025
    • Site details revised at 34 of 34 sites
  2. Study sites: 26 to 34 Interventions: Furmonertinib Mesilate Tablets Monotherapy (Drug), RC108 plus Furmonertinib Mesilate Tablets (Drug) to Furmonertinib Mesilate Tablets Monotherapy (Drug), RC108 (Drug)v2 Show 1 more changeShow less
    • Interventions: Furmonertinib Mesilate Tablets Monotherapy (Drug), RC108 plus Furmonertinib Mesilate Tablets (Drug) to Furmonertinib Mesilate Tablets Monotherapy (Drug), RC108 (Drug)
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC
Trial Details
NCT Number NCT06962865
Lead Sponsor RemeGen Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov